Suppr超能文献

[德国风湿病学会关于在SARS-CoV-2/COVID-19大流行背景下炎症性风湿性疾病患者管理的建议 - 2020年7月更新]

[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020].

作者信息

Schulze-Koops Hendrik, Iking-Konert Christof, Leipe Jan, Hoyer Bimba Franziska, Holle Julia, Moosig Frank, Aries Peer, Burmester Gerd, Fiehn Christoph, Krause Andreas, Lorenz Hanns-Martin, Schneider Matthias, Sewerin Philipp, Voormann Anna, Wagner Ulf, Krüger Klaus, Specker Christof

机构信息

Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.

Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, Pettenkoferstr. 8a, 80336, München, Deutschland.

出版信息

Z Rheumatol. 2020 Sep;79(7):679-685. doi: 10.1007/s00393-020-00851-x.

Abstract

A few days after the SARS-CoV-2 infection was declared a pandemic, the German Society for Rheumatology (DGRh) compiled first recommendations for the care of patients with inflammatory rheumatic diseases (IRD). These first recommendations were based on an expert consensus and were largely non-evidence-based. Now that the first scientific data from registers, cross-sectional studies, case reports and case series are available, the present update is intended to update the previous recommendations and to add new findings. The current recommendations are based on a literature search of publications available up to 15 June 2020 and address preventive measures (such as hygiene measures or vaccinations) and the use of immunomodulatory/immunosuppressive drugs. An important goal of the current recommendations is also to prevent harm to patients with IRD through unjustified restriction of care. The DGRh will continue to update its recommendations in the case of new aspects and will publish them as well as further information on the COVID-19 pandemic on its homepage ( www.dgrh.de ) in an ongoing process.

摘要

在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染被宣布为大流行几天后,德国风湿病学会(DGRh)编写了关于炎症性风湿性疾病(IRD)患者护理的首批建议。这些首批建议基于专家共识,且在很大程度上缺乏循证依据。鉴于现在已有来自登记处、横断面研究、病例报告和病例系列的首批科学数据,本次更新旨在更新先前的建议并补充新发现。当前建议基于对截至2020年6月15日可得出版物的文献检索,涉及预防措施(如卫生措施或疫苗接种)以及免疫调节/免疫抑制药物的使用。当前建议的一个重要目标也是防止因不合理的护理限制而对IRD患者造成伤害。DGRh将在出现新情况时继续更新其建议,并将在其主页(www.dgrh.de)上持续发布这些建议以及关于2019冠状病毒病大流行的更多信息。

相似文献

6
Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic.
Korean J Intern Med. 2020 Nov;35(6):1317-1332. doi: 10.3904/kjim.2020.417. Epub 2020 Sep 15.
8
[The German COVID-19 rheumatism register].
Z Rheumatol. 2024 Sep;83(7):536-543. doi: 10.1007/s00393-024-01516-9. Epub 2024 May 30.
9
How did COVID-19 pandemic changed the Portuguese rheumatology?
Acta Reumatol Port. 2020 Jun 8;45(Jan-Mar (1)):5-6.
10
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.
Ann Rheum Dis. 2020 Jul;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877. Epub 2020 Jun 5.

本文引用的文献

1
Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab.
Semin Arthritis Rheum. 2020 Oct;50(5):1087-1088. doi: 10.1016/j.semarthrit.2020.06.013. Epub 2020 Jun 30.
3
[Impact of COVID-19 on rheumatological care : A national survey in April 2020].
Z Rheumatol. 2020 Aug;79(6):584-589. doi: 10.1007/s00393-020-00833-z.
4
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Ann Rheum Dis. 2021 May;80(5):e67. doi: 10.1136/annrheumdis-2020-218075. Epub 2020 Jun 26.
7
Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China.
Ann Rheum Dis. 2020 Aug;79(8):1007-1013. doi: 10.1136/annrheumdis-2020-217627. Epub 2020 May 22.
10
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验